U.S. and China Reach Temporary Truce in Trade Dispute

A new immunotherapy, nicknamed immunoablative therapy, has reportedly led to the complete remission of cancer in 84 out of 103 patients with specific genetic mutations, including those with esophageal, stomach, and colorectal cancers. This innovative treatment employs dostarlimab, a humanized mouse antibody developed by AnaptysBio, which targets the PD-1 protein, allowing the immune system to attack tumor cells more effectively, according to research published in the New England Journal of Medicine.
Previously, the technique achieved a 100% tumor elimination rate in a small group with rectal cancer, prompting researchers to expand the study. "These are incredible results," remarked oncologist Luis Alberto Díaz from Memorial Sloan Kettering Cancer Center, emphasizing the potential for a new standard of care without expensive and invasive therapies like chemotherapy and surgery.
Despite the promise shown, the treatment can cost around $55,000 per patient. While further research is needed to confirm long-term benefits, experts like Ana Fernández Montes view this as a significant advancement in cancer treatment, marking an exciting era for patients.